January 9, 2023
1 minute read
Quanterix Corp. announces validation of a laboratory-developed test to quantitatively measure neurofilament light chains in serum as an aid in evaluating people who may have neurodegenerative diseases. bottom.
According to a Quanterix press release, neurofilament light chain (NfL) is a well-studied biomarker of nerve axonal injury and broadly applicable to various neurological conditions.
Injuries or injuries that result in neuronal damage can cause the release of NfL into interstitial and cerebrospinal fluid. Some of these proteins diffuse into the blood, and their concentrations are typically 50- to 100-fold lower than in CSF, making them difficult to measure.
According to the release, in 2022 the FDA granted breakthrough device designation to Quanterix’s Simoa NfL test as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS.
“Evaluating and monitoring brain health is very difficult and is usually done with limited methods such as surgery and imaging,” said Quanterix CEO. Massoud Torue mentioned in the release. “We believe that NfL is not only an important marker of neurodegenerative disease, but also an important indicator of brain-related side effects in chemotherapy, CAR T-cell therapy, and stroke.”
Quanterix’s Simoa NfL test is delivered through the company’s accelerator lab. This lab is a licensed and accredited laboratory fully equipped to support clinical diagnostic testing and translational research.